A target safety assessment of the potential toxicological risks of targeting plasmepsin IX/X for the treatment of malaria.
Journal
Toxicology research
ISSN: 2045-452X
Titre abrégé: Toxicol Res (Camb)
Pays: England
ID NLM: 101587950
Informations de publication
Date de publication:
Mar 2021
Mar 2021
Historique:
received:
28
08
2020
revised:
30
11
2020
accepted:
07
12
2020
entrez:
22
4
2021
pubmed:
23
4
2021
medline:
23
4
2021
Statut:
epublish
Résumé
The aspartic proteases plasmepsin IX/X are important antimalarial drug targets due to their specificity to the malaria parasite and their vital role as mediators of disease progression. Focusing on parasite-specific targets where no human homologue exists reduces the possibility of on-target drug toxicity. However, there is a risk of toxicity driven by inadequate selectivity for plasmepsins IX/X in Plasmodium over related mammalian aspartic proteases. Of these, CatD/E may be of most toxicological relevance as CatD is a ubiquitous lysosomal enzyme present in most cell types and CatE is found in the gut and in erythrocytes, the clinically significant site of malarial infection. Based on mammalian aspartic protease physiology and adverse drug reactions (ADRs) to FDA-approved human immunodeficiency virus (HIV) aspartic protease inhibitors, we predicted several potential toxicities including β-cell and congenital abnormalities, hypotension, hypopigmentation, hyperlipidaemia, increased infection risk and respiratory, renal, gastrointestinal, dermatological, and other epithelial tissue toxicities. These ADRs to the HIV treatments are likely to be a result of host aspartic protease inhibition due a lack of specificity for the HIV protease; plasmepsins are much more closely related to human CatD than to HIV proteinase. Plasmepsin IX/X inhibition presents an opportunity to specifically target Plasmodium as an effective antimalarial treatment, providing adequate selectivity can be obtained. Potential plasmepsin IX/X inhibitors should be assayed for inhibitory activity against the main human aspartic proteases and particularly CatD/E. An investigative rodent study conducted early in drug discovery would serve as an initial risk assessment of the potential hazards identified.
Identifiants
pubmed: 33884171
doi: 10.1093/toxres/tfaa106
pii: tfaa106
pmc: PMC8045587
doi:
Types de publication
Journal Article
Review
Langues
eng
Pagination
203-213Informations de copyright
© The Author(s) 2021. Published by Oxford University Press. All rights reserved. For Permissions, please email: journals.permissions@oup.com.
Références
Eur J Med Chem. 2019 Feb 1;163:344-352
pubmed: 30529637
Adv Anat Pathol. 2012 Jan;19(1):66-73
pubmed: 22156835
J Enzyme Inhib. 1987;1(3):169-85
pubmed: 3334243
Nat Rev Drug Discov. 2014 Jun;13(6):419-31
pubmed: 24833294
Arch Histol Cytol. 2002 Oct;65(4):359-68
pubmed: 12501893
Arterioscler Thromb Vasc Biol. 2003 Aug 1;23(8):1430-6
pubmed: 12750117
Lancet Infect Dis. 2019 Sep;19(9):943-951
pubmed: 31345709
J Mol Recognit. 2011 Mar-Apr;24(2):165-81
pubmed: 21360607
Nat Commun. 2016 Oct 11;7:13042
pubmed: 27727204
EMBO J. 1995 Aug 1;14(15):3599-608
pubmed: 7641679
Clin Sci (Lond). 2011 Mar;120(5):169-78
pubmed: 21087212
J Biochem. 2003 Dec;134(6):893-902
pubmed: 14769879
Drugs. 2007;67(12):1767-92
pubmed: 17683174
Nat Rev Microbiol. 2018 Mar;16(3):156-170
pubmed: 29355852
J Biol Chem. 2006 Mar 3;281(9):5406-15
pubmed: 16354654
Lab Invest. 2008 Mar;88(3):256-63
pubmed: 18195689
Curr Genomics. 2011 Sep;12(6):417-27
pubmed: 22379395
Kidney Int. 2013 Nov;84(5):861-3
pubmed: 24172729
Protein J. 2017 Oct;36(5):385-396
pubmed: 28762197
Expert Opin Investig Drugs. 2019 Nov;28(11):967-975
pubmed: 31661331
Trends Parasitol. 2001 Nov;17(11):532-7
pubmed: 11872398
Toxicol Sci. 2019 Feb 1;167(2):307-321
pubmed: 30371856
J Cell Biochem. 2018 Nov 14;:
pubmed: 30430636
J Biol Chem. 2007 Jan 19;282(3):1851-62
pubmed: 17095504
Nat Microbiol. 2018 Apr;3(4):447-455
pubmed: 29459732
J Biol Chem. 1989 Aug 15;264(23):13403-6
pubmed: 2760027
PLoS One. 2016 Jan 05;11(1):e0144917
pubmed: 26730818
J Cell Sci. 2004 Oct 1;117(Pt 21):5155-64
pubmed: 15456852
Science. 2017 Oct 27;358(6362):518-522
pubmed: 29074774
J Immunother Cancer. 2019 Feb 4;7(1):29
pubmed: 30717773
Life Sci. 2019 Feb 15;219:163-181
pubmed: 30641084
J Neurochem. 2014 Jul;130(1):4-28
pubmed: 24646365
Protein J. 2019 Dec;38(6):616-627
pubmed: 31586296
Antimicrob Agents Chemother. 2009 Dec;53(12):4968-78
pubmed: 19752273
Antimicrob Agents Chemother. 2007 Feb;51(2):759-62
pubmed: 17088482
Nature. 1978 Feb 16;271(5646):618-21
pubmed: 24179
HIV Med. 2005 Jan;6(1):1-6
pubmed: 15670245
Trends Parasitol. 2016 Apr;32(4):284-295
pubmed: 26778295
J Cell Biol. 2012 Sep 17;198(6):961-71
pubmed: 22986493
J Biol Chem. 2020 Jun 19;295(25):8425-8441
pubmed: 32366462
Curr Top Med Chem. 2019;18(23):2022-2028
pubmed: 30499404
Crit Rev Biochem Mol Biol. 2003;38(2):89-119
pubmed: 12749695
FEBS J. 2008 Apr;275(8):1698-707
pubmed: 18312598
Antimicrob Agents Chemother. 2006 Feb;50(2):639-48
pubmed: 16436721
Annu Rev Physiol. 2001;63:555-78
pubmed: 11181967
Proc Natl Acad Sci U S A. 2002 Jan 22;99(2):990-5
pubmed: 11782538
PLoS Pathog. 2017 Jul 6;13(7):e1006453
pubmed: 28683142
Nat Struct Mol Biol. 2012 Jan 05;19(1):9-16
pubmed: 22218294
J Infect Dis. 2003 Sep 1;188(5):635-42
pubmed: 12934178
Food Chem. 2018 Dec 1;268:94-100
pubmed: 30064809
Biochem J. 1970 Apr;117(3):601-7
pubmed: 5419752
J Biochem. 2006 Jul;140(1):57-66
pubmed: 16877769
Biochem Biophys Res Commun. 2008 Mar 14;367(3):517-22
pubmed: 18178150
Clin Sci (Lond). 2018 Jul 9;132(13):1383-1401
pubmed: 29986878
Crit Rev Oncol Hematol. 2008 Oct;68(1):12-28
pubmed: 18396408
Brain. 2006 Jun;129(Pt 6):1438-45
pubmed: 16670177
Lancet. 2018 Apr 21;391(10130):1608-1621
pubmed: 29631781
J Biol Chem. 2002 Feb 15;277(7):4687-93
pubmed: 11741910
Drug Discov Today. 2018 Dec;23(12):1925-1928
pubmed: 29803936
J Infect Dis. 2001 Sep 15;184(6):770-6
pubmed: 11517439
Science. 2017 Oct 27;358(6362):522-528
pubmed: 29074775
Nat Rev Drug Discov. 2015 Jul;14(7):475-86
pubmed: 26091267
Rocz Akad Med Bialymst. 1997;42 Suppl 1:79-85
pubmed: 9337526
EMBO J. 2013 Jul 17;32(14):2015-28
pubmed: 23792428
J Infect Dis. 2005 Aug 15;192(4):705-6
pubmed: 16028143
Pharmacol Ther. 2000 May;86(2):145-70
pubmed: 10799712
Science. 2006 Oct 27;314(5799):664-6
pubmed: 16990514
J Antimicrob Chemother. 2015 Apr;70(4):1130-8
pubmed: 25538166
Brain. 2006 Jun;129(Pt 6):1353-6
pubmed: 16738059
J Infect Dis. 2004 Dec 1;190(11):1998-2000
pubmed: 15529265
Biostatistics. 2019 Apr 1;20(2):273-286
pubmed: 29394327
HIV Med. 2019 Aug;20(7):429-438
pubmed: 31006976
ACS Infect Dis. 2019 Feb 8;5(2):184-198
pubmed: 30554511
FEBS Lett. 1999 Nov 26;462(1-2):129-34
pubmed: 10580105
J Infect Dis. 2015 Mar 1;211(5):670-9
pubmed: 25180241
Cell Host Microbe. 2020 Apr 8;27(4):642-658.e12
pubmed: 32109369
Methods Mol Biol. 2017;1641:213-228
pubmed: 28748467